Medicxi Ventures Management Jersey Ltd Invests $35.32 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Medicxi Ventures Management Jersey Ltd purchased a new stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 22,352,000 shares of the company’s stock, valued at approximately $35,316,000. RAPT Therapeutics comprises 6.7% of Medicxi Ventures Management Jersey Ltd’s portfolio, making the stock its 4th biggest position. Medicxi Ventures Management Jersey Ltd owned 63.94% of RAPT Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of RAPT. SG Americas Securities LLC boosted its stake in RAPT Therapeutics by 401.9% in the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after acquiring an additional 42,636 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in RAPT Therapeutics by 298.2% during the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after purchasing an additional 25,130 shares during the period. Barclays PLC raised its stake in shares of RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after buying an additional 29,195 shares during the period. Readystate Asset Management LP purchased a new position in shares of RAPT Therapeutics during the 3rd quarter valued at $36,000. Finally, Los Angeles Capital Management LLC grew its stake in shares of RAPT Therapeutics by 138.1% during the 3rd quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock worth $405,000 after acquiring an additional 116,853 shares during the period. 99.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on RAPT shares. Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $8.00 to $2.00 in a research report on Monday, November 11th. Wells Fargo & Company lowered their target price on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. HC Wainwright raised RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a report on Thursday, December 26th. Stifel Nicolaus reissued a “hold” rating and set a $2.00 price objective (down previously from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $9.56.

RAPT Therapeutics Stock Performance

Shares of NASDAQ RAPT opened at $1.16 on Wednesday. The firm has a market capitalization of $40.55 million and a price-to-earnings ratio of -0.42. RAPT Therapeutics, Inc. has a 12 month low of $0.79 and a 12 month high of $27.35. The business has a 50-day moving average of $1.25 and a 200-day moving average of $1.88.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. On average, analysts predict that RAPT Therapeutics, Inc. will post -2.43 earnings per share for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.